Association between High-Density Lipoprotein Cholesterol to Apolipoprotein A-I Ratio and Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study

Hangkai Huang, Jinghua Wang, Lei Xu, Min Miao, and Chengfu Xu

Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
Department of Gastroenterology, Zhejiang University Ningbo Hospital, Ningbo 315010, China
Department of Internal Medicine, Zhenhai Lianhua Hospital, Ningbo 315207, China

Correspondence should be addressed to Chengfu Xu; xiaofu@zju.edu.cn

Received 11 December 2020; Revised 22 March 2021; Accepted 29 May 2021; Published 7 June 2021

Background. This study aimed to explore the association between high-density lipoprotein cholesterol to apolipoprotein A-I ratio (HDL-C/apo A-I) and nonalcoholic fatty liver disease (NAFLD). Methods. A total of 9025 Chinese adults were enrolled in this cross-sectional study, who presented their annual health checkups at Zhenhai Lianhua Hospital, Ningbo, during 2017. Results. The NAFLD prevalence was 33.7%, and HDL-C/apo A-I was significantly decreased in NAFLD patients, as well as in lean NAFLD and in patients with NAFLD-related advanced fibrosis (all P < 0.001). The prevalence of NAFLD and components of metabolic syndrome are inversely associated with HDL-C/apo A-I (P < 0.001). Multivariate logistic regression analysis show that HDL-C/apo A-I is inversely associated with the risk of NAFLD (odds ratio: 0.353, 95% confidence interval: 0.257–0.486; P < 0.001). Conclusions. Our results suggested that increased HDL-C/apo A-I is significantly associated with a decreased risk of NAFLD.

1. Introduction

Nonalcoholic fatty liver disease (NAFLD) is featured by excessive accumulation of lipid within hepatocytes without excess alcohol consumption and other causes of hepatic steatosis [1]. NAFLD is reported to affect about 25% of the world’s population [2], and the most recent prevalence of NAFLD is as high as 29.2% in China [3]. NAFLD is divided into two subtypes as nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). NAFL shows usually a benign nature. However, NASH is the progressive subtype of NAFLD and has an increased potential to progress to fibrosis, cirrhosis, and hepatocellular carcinoma [4]. Dulai et al. [5] observed that advanced fibrosis is positively associated with increased hepatic-related and all-cause mortality in NAFLD patients. Therefore, great emphasis should be placed on early identification of hepatic fibrosis in the progression of NAFLD.

The increasing prevalence of NAFLD is accompanying the increasing prevalence of type 2 diabetes mellitus (T2DM), obesity, and other components of metabolic syndrome (MetS) [6]. However, NAFLD is also commonly occurred in nonobese individuals [7]. Zou et al. [8] observed that nonobese NAFLD makes up 22.7% of the NAFLD in the United States, analyzed by using the 1999–2016 NHANES databases. Our previous study found that nonobese NAFLD prevalence was 7.27% in China, and 8.88% nonobese developed NAFLD during a medium of five years of follow-up [9]. Thus, great importance should be attached to the risk factors related to NAFLD in nonobese populations.

In NAFLD patients, atherogenic dyslipidemia which is characterized by decreased levels of high-density lipoprotein cholesterol (HDL-C) is common [10, 11]. Likewise, low HDL-C is common in T2DM patients [12]. Apolipoprotein A-I (apo A-I) makes up the major apolipoprotein in HDL-C and reflects antiatherogenic properties [13]. Waldman et al.
[14] observed that lower HDL-C/apo A-I predicted long-term glycemic deterioration in T2DM. However, whether HDL-C/apo A-I is associated with NAFLD remains unclear.

In this study, we conducted a cross-sectional survey to analyze the association between HDL-C/apo A-I and NAFLD. We also explored whether HDL-C/apo A-I is associated with the risk of NAFLD in lean subjects (BMI < 23 kg/m²) and with the degree of hepatic fibrosis assessed by FIB-4.

2. Materials and Methods

2.1. Study Population. A total sample of 9025 participants (6231 men and 2794 women) were drawn from adults who took their annual health examination at Zhenhai Lianhua Hospital, Ningbo, during 2017. Participants were viewed as disqualified for this study if they had a history of other etiologies of chronic liver disease including viral hepatitis or with alcohol consumption greater than 210 g/week for males and 140 g/week for females [1]. The study was approved by the Hospital Ethics Committee.

2.2. Clinical Examinations. Clinical examinations were carried out according to previous procedures [9, 15–17]. Standing height and body weight were measured in standard procedures. Waist circumference was measured when the subjects were standing up with the abdomen relaxed using an inelastic tape. Systolic and diastolic blood pressures were recorded by using a sphygmomanometer with the arm supported at the heart level.

Venous blood samples were collected after the overnight-fasting period. The biochemical markers, including liver enzymes, serum lipids, glucose, and uric acid, were measured as described by using an autoanalyzer [18]. HDL-C/apo A-I was calculated as HDL-C (mmol/L) divided by apo A-I (mmol/L).

2.3. Diagnosis of NAFLD, Metabolic Syndrome, and Advanced Hepatic Fibrosis. NAFLD was diagnosed by hepatic ultrasound according to the guidance supported by the Chinese Liver Disease Association [1]. The experienced ultrasonographers who were blind to the study design and clinical laboratory data carried out the ultrasound examination using a 3.5 MHz transducer (Nemio 20, Toshiba, Japan).

Metabolic syndrome (MetS) was diagnosed according to the definition suggested by the Asia-Pacific Working Party on NAFLD [19], with the exception of BMI, which was based on the literature that recommended BMI ≥ 23 kg/m² in Asians as the definition of overweight [20]. MetS was diagnosed if any three or more of the following were met: (i) central obesity: BMI ≥ 23 kg/m² for both genders and/or waist circumference ≥ 90 cm for males and ≥ 80 cm for females; (ii) hypertriglyceridemia: triglycerides ≥ 1.7 mmol/L; (iii) low high-density lipoprotein cholesterol (HDL-C): HDL-C < 1.03 mmol/L for males and < 1.29 mmol/L for females; (iv) elevated blood pressure: systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg; and (v) elevated fasting blood glucose: fasting blood glucose ≥ 5.6 mmol/L or previously diagnosed type 2 diabetes.

According to the guidance of the American Association for the Study of Liver Diseases [4], advanced hepatic fibrosis is defined as FIB-4 > 3.25.

2.4. Statistical Analysis. Continuous variables were presented as the mean and standard deviation (SD) when normally distributed or as the median and interquartile range (IQR) if skewed. Student’s t test, the Mann–Whitney U test, and the chi-squared (χ²) test were used for comparisons of differences between groups. Correlations between HDL-C/apo A-I and NAFLD-related metabolic features were calculated by Pearson’s or Spearman’s analysis. Univariate and multivariate logistic regression analysis (backward: Wald; cutoff for entry: P < 0.05, for removal: 0.10) was applied to assess the risk factors for NAFLD. All statistical analyses were performed using SPSS 20.0 software for Windows (SPSS Inc., Chicago, IL). P < 0.05 (2-tailed test) was considered statistically significant.

3. Results

3.1. Clinical Characteristics of the Subjects with or without NAFLD. Of the 9025 enrolled subjects, 3038 (33.7%) fulfilled the diagnostic criteria of NAFLD, and the prevalence in men and women was 38.3% and 23.2%, respectively. Clinical characteristics of the participants according to NAFLD status were presented in Table 1. NAFLD patients were older, male predominant, and had higher body mass index, waist circumference, systolic and diastolic blood pressure, alanine aminotransferase, aspartate aminotransferase, γ-glutamyl transferase, triglyceride, total cholesterol, low-density lipoprotein cholesterol, fasting plasma glucose, serum uric acid, and glycated hemoglobin A1c, but had lower levels of serum HDL-C and apo A-I than NAFLD-free subjects. These results suggested that metabolic parameters were less favorable in NAFLD patients compared with the controls. Notably, we found NAFLD patients had markedly lower HDL-C/apo A-I than controls (1.00 (0.88–1.13) versus 1.02 (0.91–1.13), P < 0.001; Table 1). Our subgroup analysis found that HDL-C/apo A-I was significantly lower in lean NAFLD patients (BMI < 23 kg/m²) than that in lean controls (1.00 (0.87–1.11) versus 1.01 (0.92–1.13), P < 0.001). Regarding to hepatic fibrosis assessed by FIB-4, we found that NAFLD patients with advanced fibrosis (FIB-4 > 3.25) had significantly lower HDL-C/apo A-I than controls (0.95 (0.81–1.11) versus 1.02 (0.91–1.13), P < 0.001). These results suggested that HDL-C/apo A-I may be also associated with lean NAFLD and NAFLD-related advanced fibrosis.

3.2. Association between HDL-C/apo A-I and Prevalence of NAFLD. We classified all the subjects into two groups according to the median level of HDL-C/apo A-I (1.01). We found that subjects with HDL-C/apo A-I ≥ 1.01 had significantly higher prevalence of NAFLD than those with HDL-C/apo A-I < 1.01 (35.3% versus 32.0%, χ² = 10.988, P < 0.001). Besides, we observed a significantly higher prevalence of main components of MetS including...
hypertriglyceridemia, hypertension, and low HDL-C in subjects with HDL-C/apo A-I ≥1.01 compared with those with HDL-C/apo A-I <1.01 (Table 2).

### 3.3. Association between HDL-C/apo A-I and NAFLD-Related Metabolic Parameters

To better understand the association between HDL-C/apo A-I and NAFLD, we further analyzed the correlation between HDL-C/apo A-I and metabolic features. Spearman's analysis showed that HDL-C/apo A-I was significantly and negatively associated with systolic blood pressure, alanine aminotransferase, aspartate aminotransferase, γ-glutamyl transferase, triglyceride, fasting plasma glucose, and glycated hemoglobin A1c (Table 3). These results indirectly support the association between HDL-C/apo A-I and NAFLD.

### 3.4. Association between HDL-C/apo A-I and Risk of NAFLD

We performed univariate and multivariate logistic regression analysis to explore whether HDL-C/apo A-I is independently associated with the risk of NAFLD. In the univariate model, HDL-C/apo A-I was significantly associated with a decreased risk of NAFLD (OR: 0.551, 95% CI: 0.433–0.701; P < 0.001) (Table 4). In the multivariate model, after adjusting for body mass index, diastolic blood pressure, alanine aminotransferase, γ-glutamyl transferase, total cholesterol, uric acid, and glycated hemoglobin A1c, HDL-C/apo A-I remained significantly associated with the risk of NAFLD (OR: 0.353, 95% CI: 0.257–0.486, P < 0.001) (Table 5). These results further support a negative association between HDL-C/apo A-I and NAFLD.

### 4. Discussion

In this study, we found that HDL-C/apo A-I was negatively associated with NAFLD. First, HDL-C/apo A-I was significantly decreased in NAFLD patients, as well as in lean NAFLD and in patients with NAFLD-related advanced fibrosis. Second, HDL-C/apo A-I was negatively associated with the prevalence of NAFLD. Third, HDL-C/apo A-I was negatively and independently associated with the risk of NAFLD.

The serum levels of HDL-C have been shown to be negatively associated with cardiovascular disease (CVD) risks. Therefore, many clinical trials aimed at increasing HDL-C levels have been carried out to see whether this strategy could benefit decreasing CVD burden. However, neither cholesterol ester transfer protein inhibitors nor niacin as powerful HDL-C-level-increasing drugs is effective for decreasing cardiovascular event rates [21, 22].

Notably, HDL is a heterogeneous particle, varying in size, composition, and function, and thus, HDL particles rather than the levels of HDL-C are better biomarkers of the role of HDL. As predicted by Shen [23], Mazer et al. [24] observed the quasilinear relationship between HDL size and HDL-C/apo A-I among the Women’s Health Study Data. HDL-C/apo A-I, an indicator of HDL particle size and cholesterol composition, and function, and thus, HDL particles rather than cholesterol ester transfer protein inhibitors or niacin as powerful HDL-C-level-increasing drugs is effective for decreasing cardiovascular event rates [21, 22].

Table 1: Comparison of clinical characteristics between the participants with and without NAFLD.

| Variables                      | With NAFLD (n = 3038) | Without NAFLD (n = 5987) | Z value | P value |
|-------------------------------|-----------------------|---------------------------|---------|---------|
| Age (year)                    | 52 (43–63)            | 49 (39–62)                | −7.577  | <0.001  |
| Gender (male/female, n)       | 2389/649              | 3842/2145                 | 197.283 | <0.001  |
| Body mass index (kg/m²)       | 25.10 (23.53–27.00)   | 22.00 (20.40–23.70)       | −49.467 | <0.001  |
| Waist circumference (cm)      | 89 (85–94)            | 80 (74–86)                | −44.467 | <0.001  |
| Systolic blood pressure (mmHg)| 132 (122–142)         | 124 (113–135)             | −22.649 | <0.001  |
| Diastolic blood pressure (mmHg)| 80 (72–87)           | 73 (66–81)                | −24.292 | <0.001  |
| Alanine aminotransferase (U/L)   | 26 (19–40)          | 17 (13–23)                | −38.158 | <0.001  |
| Aspartate aminotransferase (U/L)   | 23 (19–29)        | 20 (17–25)                | −21.456 | <0.001  |
| γ-Glutamyl transferase (U/L)   | 32 (23–50)           | 20 (15–28)                | −37.811 | <0.001  |
| Triglyceride (mmol/L)          | 1.83 (1.34–2.56)      | 1.13 (0.85–1.56)          | −40.646 | <0.001  |
| Total cholesterol (mmol/L)     | 4.99 (4.38–5.65)      | 4.71 (4.14–5.35)          | −12.828 | <0.001  |
| HDL-C (mmol/L)                 | 1.19 (1.03–1.35)      | 1.31 (1.15–1.49)          | −21.573 | <0.001  |
| LDL-C (mmol/L)                 | 2.82 (2.34–3.33)      | 2.74 (2.31–3.22)          | −4.408  | <0.001  |
| Apo A-I (mmol/L)               | 1.18 (1.05–1.32)      | 1.27 (1.12–1.46)          | −18.130 | <0.001  |
| Fasting plasma glucose (mmol/L)| 5.42 (5.05–5.97)      | 5.18 (4.91–5.54)          | −18.705 | <0.001  |
| Serum uric acid (μmol/L)       | 382 (329–434)         | 328 (276–380)             | −28.709 | <0.001  |
| HbA1c (%)                      | 5.50 (5.20–5.90)      | 5.30 (5.10–5.60)          | −21.146 | <0.001  |
| HDL-C/apo A-I                  | 1.00 (0.88–1.13)      | 1.02 (0.91–1.13)          | −5.207  | <0.001  |

Data are presented as median (IQR) due to skewed distribution. *χ² value; apo A-I, apolipoprotein A-I; HbA1c, glycated hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; HDL-C/apo A-I, high-density lipoprotein cholesterol to apolipoprotein A-I ratio; LDL-C, low-density lipoprotein cholesterol; NAFLD, nonalcoholic fatty liver disease.
HDL-C/apo A-I ratio) is associated with an increased risk of that cholesterol-rich and apo A-I-poor HDL particle (high-density lipoprotein cholesterol to apolipoprotein A-I ratio). HDL-C: high-density lipoprotein cholesterol; HDL-C/apo A-I: high-density lipoprotein cholesterol to apolipoprotein A-I ratio; NAFLD: nonalcoholic fatty liver disease.

### Table 2: Prevalence rate of NAFLD and MetS components in participants with HDL-C/apo A-I greater or less than 1.01.

| Variables                                  | Participants with HDL-C/apo A-I ≥1.01 | Participants with HDL-C/apo A-I <1.01 | P value |
|--------------------------------------------|--------------------------------------|--------------------------------------|---------|
| NAFLD (%)                                  | 35.3                                 | 32.0                                 | <0.001  |
| Hypertension (%)                           | 39.9                                 | 25.0                                 | <0.001  |
| Hypertension (%)                           | 48.5                                 | 44.2                                 | <0.001  |
| Low HDL-C (%)                              | 38.0                                 | 9.7                                  | <0.001  |

### Table 3: Correlations between HDL-C/apo A-I and metabolic parameters.

| Variables       | SBP       | ALT       | AST       | GGT       | TG        | FPG       | HbA1c      |
|-----------------|-----------|-----------|-----------|-----------|-----------|-----------|------------|
| r value         | −0.062    | −0.063    | −0.123    | −0.078    | −0.200    | −0.057    | −0.029     |
| P value         | <0.001    | <0.001    | <0.001    | <0.001    | <0.001    | <0.001    | 0.005      |

ALT, alanine aminotransferase; AST, aspartate aminotransferase; FPG, fasting plasma glucose; GGT, γ-glutamyl transferase; HbA1c, glycated hemoglobin A1c; SBP, systolic blood pressure; TG, triglyceride.

### Table 4: Univariable analysis for factors associated with NAFLD.

| Variables                                   | OR         | 95% CI     | P value |
|---------------------------------------------|------------|------------|---------|
| Gender (male/female)                        | 2.055      | 1.857–2.275| <0.001  |
| Age (year)                                  | 1.011      | 1.008–1.013| <0.001  |
| Body mass index (kg/m²)                     | 1.635      | 1.598–1.674| <0.001  |
| Waist circumference (cm)                    | 1.149      | 1.141–1.157| <0.001  |
| Systolic blood pressure (mmHg)              | 1.030      | 1.027–1.032| <0.001  |
| Diastolic blood pressure (mmHg)             | 1.053      | 1.048–1.057| <0.001  |
| Alanine aminotransferase (U/L)              | 1.056      | 1.052–1.060| <0.001  |
| Aspartate aminotransferase (U/L)            | 1.050      | 1.045–1.056| <0.001  |
| γ-Glutamyl transferase (U/L)                | 1.020      | 1.018–1.022| <0.001  |
| Triglyceride (mmol/L)                       | 2.770      | 2.600–2.951| <0.001  |
| Total cholesterol (mmol/L)                  | 1.339      | 1.279–1.402| <0.001  |
| LDL-C (mmol/L)                              | 1.145      | 1.078–1.216| <0.001  |
| Fasting plasma glucose (mmol/L)             | 1.478      | 1.408–1.552| <0.001  |
| Serum uric acid (μmol/L)                    | 1.008      | 1.008–1.009| <0.001  |
| HbA1c (%)                                   | 2.062      | 1.902–2.235| <0.001  |
| HDL-C/apo A-I                               | 0.551      | 0.433–0.701| <0.001  |

HbA1c, glycated hemoglobin A1c; HDL-C/apo A-I, high-density lipoprotein cholesterol to apolipoprotein A-I ratio; LDL-C, low-density lipoprotein cholesterol.

### Table 5: Multivariable analysis for factors associated with NAFLD.

| Variables                                   | OR         | 95% CI     | P value |
|---------------------------------------------|------------|------------|---------|
| Body mass index (kg/m²)                     | 1.504      | 1.467–1.541| <0.001  |
| Diastolic blood pressure (mmHg)             | 1.022      | 1.016–1.027| <0.001  |
| Alanine aminotransferase (U/L)              | 1.032      | 1.027–1.036| <0.001  |
| γ-Glutamyl transferase (U/L)                | 1.002      | 1.000–1.004| 0.015   |
| Total cholesterol (mmol/L)                  | 1.297      | 1.219–1.381| <0.001  |
| HbA1c (%)                                   | 1.628      | 1.494–1.774| <0.001  |
| Serum uric acid (μmol/L)                    | 1.004      | 1.003–1.004| <0.001  |
| HDL-C/apo A-I                               | 0.353      | 0.257–0.486| <0.001  |

HbA1c, glycated hemoglobin A1c; HDL-C/apo A-I, high-density lipoprotein cholesterol to apolipoprotein A-I ratio.

that cholesterol-rich and apo A-I-poor HDL particle (high HDL-C/apo A-I ratio) is associated with an increased risk of preclinical atherosclerosis.

In contrast, regarding long-term progression of hyperglycemia in T2DM patients, lower HDL-C/apo A-I was found to predict earlier and greater uptake of pharmacologic glucose control for those who only need lifestyle intervention at baseline [14]. Similarly, Abbasi et al. [29] found that higher HDL-C/apo A-I was significantly related to a lower risk of incident T2DM. These contradictory observations may be the result of different roles of HDL in the pathogenesis of CVD and T2DM, or different ethics. Furthermore, NAFLD is believed to be closely related to lifestyle-related diseases such as CVD and T2DM. To the best of our knowledge, this is the first study to reveal that HDL-C/apo A-I levels were significantly and independently associated with NAFLD.

Various lipoproteins and apolipoproteins are closely related to the risk of NAFLD. A cross-sectional study involving 9162 individuals in South Korea found that compared with the first quartile of apolipoprotein B to A-I ratio (apo B/apo A-I), the fourth quartile of apo B/A-I was associated with 1.359-fold risk of NAFLD [30]. Apo B/apo A-I was also positively associated with carotid intima media thickness in NAFLD patients [31]. Besides, elevated serum apolipoprotein E, very-low-density lipoprotein, and low-density lipoprotein were independently associated with NAFLD [32, 33].

The underlying mechanism linking HDL-C/apo A-I to NAFLD remains to be elucidated. There are several possible explanations. First, systemic low-grade inflammation has played a central role in the pathogenesis of NAFLD. HDL particles display anti-inflammatory functions via inhibiting production of multiple proinflammatory cytokines and chemokines and decreasing adhesion molecule expression [34]. Regarding T2DM, reduced HDL-C/apo A-I is thought to promote islet cell stress via association of systemic low-grade inflammation [14]. Second, oxidative stress is a well-known risk factor in the progression of NAFLD [35]. HDL particles represent to accept oxidized lipids and to inhibit LDL oxidation, especially in the process of atherosclerosis [34]. Third, HDL particles promote cholesterol efflux from macrophage foam cells, and drugs aimed at promoting reverse cholesterol transport showed protective function in liver steatosis [36]. Fourth, insulin resistance is the main component of NAFLD, and an inverse association was found between HDL particle size and insulin resistance. To be more specific, insulin resistance progression was
related to an increase of small HDL particles and a decrease of large HDL particles measured by nuclear magnetic resonance [37].

Our study has several limitations. First, NAFLD was diagnosed by hepatic ultrasonography which is not sensitive for mild hepatic steatosis. Second, the determination of causality is not clear in the cross-sectional design. Third, with regard to the underlying mechanisms of association between HDL-C/apo A-I and NAFLD, we did not assess markers of systemic low-grade inflammation such as high-sensitivity C response protein, interleukin-6. Similarly, insulin resistance was not examined. Fourth, in this study, we assessed the degree of hepatic fibrosis by FIB-4, which is a cost-effective and noninvasive diagnostic score for assessing fibrosis in NAFLD patients [4]. But, its ability to exclude advanced fibrosis is more useful than identifying it [38]. Although the diagnostic utility has been shown to be accurate in several clinical settings [39], its diagnostic ability is limited in individuals aged ≤35 years or aged ≥65 years [40].

In conclusion, our large cross-sectional study suggests that HDL-C/apo A-I, a useful surrogate biomarker for HDL particle size, is inversely associated with NAFLD.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

Hangkai Huang performed the statistical analysis and wrote the manuscript. Jinhua Wang took part in the statistical analysis. Lei Xu and Min Miao collected the data. Chengfu Xu was responsible for the study design and revision of the manuscript. All authors read and approved the final manuscript.

Acknowledgments

This work was supported by the Key Research and Development Program of Zhejiang Province (2020C03033), National Natural Science Foundation of China (Nos. 81722009 and 81770573), and National Key Research and Development Program (No. 2018YFA0109800).

References

[1] J. G. Fan, L. Wei, H. Zhuang et al., "Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China)," Journal of Digestive Diseases, vol. 20, no. 4, pp. 163–173, 2019.
[2] Z. Younossi, F. Tacke, M. Arrese et al., "Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis," Hepatology, vol. 69, no. 6, pp. 2672–2682, 2019.
[3] F. Zhou, J. Zhou, W. Wang et al., "Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis," Hepatology, vol. 70, no. 4, pp. 1119–1133, 2019.
[4] N. Chalasani, Z. Younossi, J. E. Lavine et al., "The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases," Hepatology, vol. 67, no. 1, pp. 328–357, 2018.
[5] P. S. Dulai, S. Singh, J. Patel et al., "Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis," Hepatology, vol. 65, no. 5, pp. 1557–1565, 2017.
[6] Z. Younossi, Q. M. Anstee, M. Marietti et al., "Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention," Nature Reviews Gastroenterology & Hepatology, vol. 15, no. 1, pp. 11–20, 2018.
[7] Q. Ye, B. Zou, Y. H. Yeo et al., "Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis," The Lancet Gastroenterology & Hepatology, vol. 5, no. 8, pp. 739–752, 2020.
[8] B. Zou, Y. H. Yeo, V. H. Nguyen, R. Cheung, E. Ingelsson, and M. H. Nguyen, "Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999–2016," Journal of Internal Medicine, vol. 288, no. 1, pp. 139–151, 2020.
[9] C. Xu, C. Yu, H. Ma, L. Xu, M. Miao, and Y. Li, "Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai study," American Journal of Gastroenterology, vol. 108, no. 8, pp. 1299–1304, 2013.
[10] W. Nseir, A. Shalata, A. Marmor, and N. Assy, "Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease," Digestive Diseases and Sciences, vol. 56, no. 12, pp. 3439–3449, 2011.
[11] G. Targher, C. P. Day, and E. Bonora, "Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease," New England Journal of Medicine, vol. 363, no. 14, pp. 1341–1350, 2010.
[12] R. W. Grant and J. B. Meigs, "Prevalence and treatment of low HDL cholesterol among primary care patients with type 2 diabetes: an unmet challenge for cardiovascular risk reduction," Diabetes Care, vol. 30, no. 3, pp. 479–484, 2007.
[13] M. H. Yang, J. Sung, and G.-Y. Gwak, "The associations between apolipoprotein B, A1, and the B/A1 ratio and nonalcoholic fatty liver disease in both normal-weight and overweight Korean population," Journal of Clinical Lipidology, vol. 10, no. 2, pp. 289–298, 2016.
[14] B. Waldman, A. J. Jenkins, T. M. E. Davis et al., "HDL-C and HDL-C/ApoA-I predict long-term progression of glycemia in established type 2 diabetes," Diabetes Care, vol. 37, no. 8, pp. 2351–2358, 2014.
[15] J. Wang, L. Ma, S. Chen et al., "Risk for the development of non-alcoholic fatty liver disease: a prospective study," Journal of Gastroenterology and Hepatology, vol. 33, no. 8, pp. 1518–1523, 2018.
[16] J. Wang, W. Zhu, S. Huang et al., "Serum apoB levels independently predict the development of non-alcoholic fatty liver disease: a 7-year prospective study," Liver International, vol. 37, no. 8, pp. 1202–1208, 2017.
[17] L. Xu, J. Xie, S. Chen et al., "Light-to-moderate alcohol consumption is associated with increased risk of type 2 diabetes in individuals with nonalcoholic fatty liver disease: a nine-year cohort study," American Journal of Gastroenterology, vol. 115, no. 6, pp. 876–884, 2020.
[18] Z.-Y. Lu, C. Cen, Z. Shao, X.-H. Chen, C.-F. Xu, and Y.-M. Li, "Association between serum α-L-fucosidase and non-alcoholic fatty liver disease: cross-sectional study," *World Journal of Gastroenterology*, vol. 22, no. 5, pp. 1884–1890, 2016.

[19] J.-G. Fan, "Epidemiology of alcoholic and nonalcoholic fatty liver disease in China," *Journal of Gastroenterology and Hepatology*, vol. 28, no. S1, pp. 11–17, 2013.

[20] J.-G. Fan, S.-U. Kim, and V. W.-S. Wong, "New trends on CETP-inhibition and HDL-cholesterol: a story between HDL size and the ratio of HDL cholesterol to apolipoprotein A-I concentrations changes the inverse direction of the relationship between high HDL-C concentration and a measure of pre-clinical atherosclerosis," *Atherosclerosis*, vol. 231, no. 2, pp. 181–186, 2013.

[21] W. E. Boden, J. L. Probstfield, T. Anderson et al., "Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy," *New England Journal of Medicine*, vol. 365, no. 24, pp. 2255–2267, 2011.

[22] S. J. Nicholls, "CETP-inhibition and HDL-cholesterol: a story of CV risk or CV benefit, or both," *Clinical Pharmacology & Therapeutics*, vol. 104, no. 2, pp. 297–300, 2018.

[23] B. W. Shen, A. M. Scanu, and F. J. Kézdy, "Structure of human serum lipoproteins inferred from compositional analysis," *Proceedings of the National Academy of Sciences*, vol. 74, no. 3, pp. 837–841, 1977.

[24] N. A. Mazer, F. Giulianini, N. P. Paynter, P. Jordan, and B. W. Shen, A. M. Scanu, and F. J. Kézdy, "Structure of human serum lipoproteins inferred from compositional analysis," *Proceedings of the National Academy of Sciences*, vol. 74, no. 3, pp. 837–841, 1977.

[25] K.-C. Sung, S. H. Wild, and C. D. Byrne, "Controlling for apolipoprotein A-I with experimental results from the women’s health study," *Clinical Chemistry*, vol. 59, no. 6, pp. 949–958, 2013.

[26] K.-C. Sung, S. Ryu, S. H. Wild, and C. D. Byrne, "An increased high-density lipoprotein cholesterol/apolipoprotein A-I ratio is associated with increased cardiovascular and all-cause mortality," *Heart*, vol. 101, no. 7, pp. 553–558, 2015.

[27] K.-C. Sung, S. H. Wild, and C. D. Byrne, "Controlling for apolipoprotein A-I concentrations changes the inverse direction of the relationship between high HDL-C concentration and a measure of pre-clinical atherosclerosis," *Atherosclerosis*, vol. 231, no. 2, pp. 181–186, 2013.

[28] P. Mani, K. Uno, J. S. John, E. M. Tuzcu, S. E. Nissen, and S. J. Nicholls, "Relation of high-density lipoprotein cholesterol: apolipoprotein a-I ratio to progression of coronary atherosclerosis in statin-treated patients," *The American Journal of Cardiology*, vol. 114, no. 5, pp. 681–685, 2014.

[29] X. L. Li, J. J. Li, Y. L. Guo et al., "The ratio of high-density lipoprotein cholesterol to apolipoprotein A-I predicts myocardial injury following elective percutaneous coronary intervention, " *Clinical Cardiology*, vol. 37, no. 9, pp. 558–565, 2014.

[30] A. Abbasi, E. Corpeleijn, R. T. Gansevoort et al., "Role of HDL cholesterol and estimates of HDL particle composition in future development of type 2 diabetes in the general population: the PREVEND study," *The Journal of Clinical Endocrinology & Metabolism*, vol. 98, no. 8, pp. E1352–E1359, 2013.

[31] Y. G. Choe, W. Jin, Y. K. Cho et al., "Apolipoprotein B/AI ratio is independently associated with non-alcoholic fatty liver disease in nondiabetic subjects," *Journal of Gastroenterology and Hepatology*, vol. 28, no. 4, pp. 678–683, 2013.

[32] R. Fadaei, R. Meshkani, H. Pouatchi et al., "Association of carotid intima media thickness with atherogenic index of plasma, apo B/apo A-I ratio and paraoxonase activity in patients with non-alcoholic fatty liver disease," *Archives of Physiology and Biochemistry*, vol. 125, no. 1, pp. 19–24, 2019.